AC Immune Doses First Participant In Phase 1 Study Of ACI-19764 Targeting Neuroinflammation In Alzheimer's, Parkinson's And ALS
Benzinga Newsdesk 8 months ago
News
ACI-19764 is an orally available highly brain-penetrant small molecule NLRP3 inhibitorNLRP3 inhibitors are a major new class of compounds linked to a broad spectrum of inflammatory conditions including both metabolic and
- ACI-19764 is an orally available highly brain-penetrant small molecule NLRP3 inhibitor
- NLRP3 inhibitors are a major new class of compounds linked to a broad spectrum of inflammatory conditions including both metabolic and neurological diseases
- ACI-19764 is an important addition to AC Immune's growing small molecule pipeline
- Phase 1 results in healthy volunteers are expected in H2 2026